The overall goal of this proposal is to elucidate the mechanism by which cholestasis triggers production of proinflammatory mediators in the liver. Cholestatic liver disease arises when excretion of bile acids from the liver is interrupted. This results in the accumulation of bile acids in the liver, hepatic inflammation, and hepatocyte injury. The pathogenesis of hepatocyte injury during cholestasis depends in part on the release of proinflammatory mediators that cause neutrophils to accumulate in the liver and become activated to damage hepatocytes. Interestingly, inflammation associated with cholestasis occurs independently of tumor necrosis factor-a or interteukin-1, suggesting that this process is regulated by a novel, previously undescribed mechanism. Our preliminary studies indicate that the transcription factor, early growth response factor-1 (Egr-1), is critical for this process. Egr-1 is rapidly upregulated in hepatocytes during cholestasis. Upregulation of Egr-1 appears to be mediated directly by bile acids, since exposure of primary mouse hepatocytes to pathological concentrations of bile acids upregulates Egr-1. Our studies show further that upregulation of macrophage inflammatory protein-2, intercellular adhesion molecule-1, neutrophil accumulation, and hepatocyte injury are dramatically reduced in Egr-1 knockout mice with cholestasis. These preliminary results suggest that upregulation of Egr-1 in hepatocytes is vital for the development of neutrophil-dependent inflammatory liver injury. Furthermore, these studies indicate that Egr-1 provides the critical link between elevated concentrations of bile acids and the production of proinflammatory mediators in liver. Therefore, the main hypothesis of this proposal is that during early stages of cholestasis, elevated concentrations of bile acids upregulate Egr-1 in hepatocytes, which increases expression of proinflammatory mediators that cause neutrophils to accumulate in the liver and become activated to damage hepatocytes. The studies in this proposal aim to test this hypothesis by: (1) elucidating the molecular mechanism(s) by which bile acids upregulate Egr-1 in hepatocytes, (2) determining whether Egr-1 regulates proinflammatory mediator expression by hepatocytes, and (3) determining whether bile acids increase proinflammatory mediator expression by hepatocytes through Egr-1-dependent mechanisms. A greater understanding of the molecular mechanism(s) by which Egr-1 mediates hepatocellular injury during cholestasis could provide insight into ways to treat this disease in humans. Furthermore, since bile acid concentrations are increased in several types of liver disease in humans, this pathway could also prove to be an important, general mechanism of inflammatory injury in the liver. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK073566-01A2
Application #
7259929
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2007-05-01
Project End
2012-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
1
Fiscal Year
2007
Total Cost
$301,350
Indirect Cost
Name
University of Kansas
Department
Pharmacology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Copple, Bryan L; Li, Tiangang (2016) Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res 104:9-21
Roth, Katherine J; Copple, Bryan L (2015) Role of Hypoxia-Inducible Factors in the Development of Liver Fibrosis. Cell Mol Gastroenterol Hepatol 1:589-597
Mochizuki, Akie; Pace, Aaron; Rockwell, Cheryl E et al. (2014) Hepatic stellate cells orchestrate clearance of necrotic cells in a hypoxia-inducible factor-1?-dependent manner by modulating macrophage phenotype in mice. J Immunol 192:3847-3857
Yang, Min; Ramachandran, Anup; Yan, Hui-Min et al. (2014) Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. Toxicol Lett 224:186-95
Ni, Hong-Min; Woolbright, Benjamin L; Williams, Jessica et al. (2014) Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol 61:617-25
Ni, Hong-Min; Bhakta, Amar; Wang, Shaogui et al. (2014) Role of hypoxia inducing factor-1? in alcohol-induced autophagy, steatosis and liver injury in mice. PLoS One 9:e115849
O'Brien, Kate M; Allen, Katryn M; Rockwell, Cheryl E et al. (2013) IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol 183:1498-1507
Kassel, Karen M; Sullivan, Bradley P; Cui, Wei et al. (2012) Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease. Am J Pathol 181:1287-95
Copple, Bryan L; Kaska, Sophia; Wentling, Callie (2012) Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther 341:307-16
Zhang, Youcai; Hong, Ji-Young; Rockwell, Cheryl E et al. (2012) Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 32:58-69

Showing the most recent 10 out of 19 publications